Natco claims the new patent unlawfully extends Novartis’s market monopoly over the breast cancer medicine past 2027; Delhi High Court issues notices to all parties.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.